Login to Your Account



Other News To Note


Wednesday, September 11, 2013

Medivir AB, of Stockholm, Sweden, said it discontinued development of its hepatitis B compound, MIV-201, based on a joint decision with Daewong Pharmaceutical Co. Ltd., of South Korea.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription